TG Therapeutics Logo
US88322Q1085
A1JXW7
TGTX

TG Therapeutics

A carregar cotações...

Previsão

O preço-alvo médio dos analistas é € 73,31 (+19,98%). A mediana é € 73,31 (+19,98%).

Comprar
  11
Manter
  1
Vender
  1

Discussões na comunidade

Ainda não há nenhuma discussão sobre este ativo.

Iniciar discussão

  • TG Therapeutics raises revenue outlook, BRIUMVI gains market share in RMS

    TG Therapeutics reports strong commercial growth of BRIUMVI in relapsing multiple sclerosis and raises its 2024 revenue guidance to $890–905 million; the company is targeting a $1 billion run rate by the end of Q4. BRIUMVI has captured more than one-third of the IV anti‑CD20 market, a simplified IV dosing regimen should ease use, and a sBLA is upcoming. A subcutaneous formulation showed about 60% bioavailability in Phase I and will be tested in Phase III against two dosing intervals; TG sees broad potential also in myasthenia gravis and treatment‑resistant schizophrenia. » Mais em de.investing.com


  • TG Therapeutics stock recovers despite earnings miss

    TG Therapeutics shares rose intraday by 5.9%, extending the recovery after the sharp sell-off following the Q2 results. The company reported EPS of $0.05 versus a consensus of about $0.44; the miss was due to higher manufacturing and operating costs, not weak revenue. Revenue increased in the second quarter to roughly $240 million (+70% YoY) and the full-year guide was raised to about $950 million; additionally, the completed enrollment of the phase-3 trial for subcutaneous BRIUMVI administration could be another catalyst. » Mais em de.investing.com


  • TG Therapeutics climbs after Briumvi outperforms expectations and positive subcutaneous data

    ClearBridge's Q2 investor letter named TG Therapeutics as a top contributor after its key drug Briumvi delivered greater-than-expected growth and positive clinical results for a subcutaneous formulation that could expand the addressable market. The stock has risen sharply over the past month and year, reflecting renewed investor interest in the company's commercial-stage multiple sclerosis franchise. » Mais em finance.yahoo.com


  • TG Therapeutics hits 52-week high at $57.40

    Shares of TG Therapeutics rose to a 52-week high of $57.40 and are up about 86% year-to-date, bringing market capitalization to $8.09 billion. InvestingPro currently rates the stock as undervalued compared with its fair value. For Q1 2026 the company missed EPS expectations ($0.12 vs. $0.28) and reported slightly lower revenue of $194.8 million. TG Therapeutics is simultaneously advancing clinical programs with Briumvi, including initiated Phase 2 studies in treatment‑resistant schizophrenia and myasthenia gravis, positive post‑hoc Phase 3 data, and a successful ENHANCE study endpoint demonstrating bioequivalence of a new single‑dose infusion regimen. » Mais em de.investing.com


  • TG Therapeutics reaches 52-week high at 54.04 USD

    Shares of TG Therapeutics rose to a 52-week high of 54.04 USD, giving the company a market capitalization of about 7.57 billion USD; the stock is up 72.76% year-to-date and gained 52.54% over the past year. Despite the share price increase, the company missed Q1 2026 estimates with EPS of 0.12 USD (expectation 0.28 USD) and revenue of 194.8 million USD (forecast 199.45 million USD). TG Therapeutics also reported progress with BRIUMVI: start of a phase-2 maintenance study in myasthenia gravis, positive phase-1 topline data and positive post-hoc results, and a successful ENHANCE bioequivalence study in multiple sclerosis. » Mais em de.investing.com

Dados financeiros da empresa

No último trimestre, TG Therapeutics registou receitas de € 229,48 mi e um ganho líquido de € 48,97 mi
(EUR) setembro de 2026
YoY
Receitas 229,48 mi 66,54%
Ganho bruto 192,34 mi 69,00%
Ganho líquido 48,97 mi 85,30%
EBITDA 79,24 mi 184,44%

Dados fundamentais

Métrica Valor
Capitalização bolsista
€ 8,64 bi
Número de ações
151,15 mi
Máximo/mínimo de 52 semanas
€ 61,96 - € 24,37
Dividendos Não
Beta
1,81
PER (PE Ratio)
84,25
PEG (PEG Ratio)
-1,11
P/VC (PB Ratio)
15,44
P/V (PS Ratio)
10,57

Perfil da empresa

A TG Therapeutics, Inc., uma empresa biofarmacêutica em fase comercial, dedica-se à aquisição, desenvolvimento e comercialização de tratamentos inovadores para neoplasias malignas de células B e doenças autoimunes. Os seus candidatos a produtos terapêuticos incluem o Ublituximab, um anticorpo monoclonal glicoengenheirado em fase de investigação para o tratamento do linfoma não Hodgkin de células B, da leucemia linfocítica crónica (LLC) e das formas recorrentes de esclerose múltipla; e o Umbralisib, um inibidor oral de PI3K-delta e CK1-epsilon para o tratamento da LLC, do linfoma da zona marginal e do linfoma folicular. A empresa desenvolve também o Cosibelimab, um anticorpo monoclonal humano do subtipo IgG1 que se liga ao ligando 1 da morte programada (PD-L1) e bloqueia as suas interações com os recetores PD-1 e B7.1; o TG-1701 é um inibidor covalentemente ligado da tirosina quinase de Bruton (BTK), de administração oral, que apresenta seletividade para a BTK em comparação com o ibrutinib em rastreios de cinases in vitro; e o TG-1801, um anticorpo biespecífico anti-CD47 e anti-CD19. Além disso, possui vários programas pré-clínicos licenciados para BET, quinase 4 associada ao recetor de interleucina-1 e GITR; e acordos de colaboração com a Checkpoint Therapeutics, Inc., a Jiangsu Hengrui Medicine Co., a Novimmune SA, a Ligand Pharmaceuticals Incorporated e a Jubilant Biosys. A empresa tem alianças estratégicas com a LFB Biotechnologies S.A.S; a GTC Biotherapeutics; a LFB/GTC LLC; a Ildong Pharmaceutical Co. Ltd.; e a Rhizen Pharmaceuticals, S A. A TG Therapeutics, Inc. foi constituída em 1993 e tem sede em Nova Iorque, Nova Iorque.

Nome
TG Therapeutics
CEO
Michael S. Weiss
Sede Morrisville, ny
EUA
Site
Setor
Cuidados de saúde
Indústria
Biotecnologia
Entrada em bolsa
03/05/2010
Colaboradores 399

Símbolos de ticker

Bolsa Símbolo
NASDAQ
TGTX
London Stock Exchange
0VGI.L
Frankfurt
NKB2.F
Düsseldorf
NKB2.DU
London
0VGI.L
SIX
NKB2.SW
München
NKB2.MU
🍪

Parqet  utiliza cookies. Saber mais